Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03780517
Title Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Boston Pharmaceuticals
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | FRA | ESP | BEL

Additional content available in CKB BOOST